Outlook Therapeutics, Inc. News Releases http://ir.oncobiologics.com/ Outlook Therapeutics, Inc. News Releases en Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019 http://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeutics-provides-business-update-and-reports-second CRANBURY, N.J. , May 15, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported business highlights and financial results for its second fiscal quarter ended March 31, 2019 . Recent Highlights: FDA acceptance and activation of the IND application for Wed, 15 May 2019 08:00:00 -0400 Outlook Therapeutics, Inc. News Releases 8126 Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical Development http://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeutics-announces-addition-jennifer-m-kissner-phd CRANBURY, N.J. , April 26, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age Fri, 26 Apr 2019 08:00:00 -0400 Outlook Therapeutics, Inc. News Releases 8116 Outlook Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants http://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeutics-announces-pricing-public-offering-common CRANBURY, N.J. , April 10, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”) announced today the pricing of an underwritten public offering of 10,340,000 shares of its common stock, 15-month warrants to purchase up to an aggregate of 10,340,000 shares of common Wed, 10 Apr 2019 09:00:00 -0400 Outlook Therapeutics, Inc. News Releases 8096 Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010 http://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeutics-announces-fda-acceptance-ind-ons-5010 Enrollment of U.S. patients in the ONS-5010-002 Phase 3 clinical trial expected to be initiated in calendar Q2 2019 CRANBURY, N.J. , April 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today the U.S. Food and Drug Administration ( FDA ) acceptance Mon, 01 Apr 2019 08:00:00 -0400 Outlook Therapeutics, Inc. News Releases 8056 Outlook Therapeutics Announces Reverse Stock Split http://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeutics-announces-reverse-stock-split CRANBURY, N.J. , March 15, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”) announced today that its Board of Directors has approved a 1-for-8 reverse stock split of the Company’s common stock, which became effective this morning immediately upon the filing by the Fri, 15 Mar 2019 09:00:00 -0400 Outlook Therapeutics, Inc. News Releases 8041 Outlook Therapeutics Regains Compliance With All Nasdaq Listing Requirements http://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeutics-regains-compliance-all-nasdaq-listing CRANBURY, N.J. , March 05, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today that the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with the applicable requirements for the continued listing Tue, 05 Mar 2019 08:00:00 -0500 Outlook Therapeutics, Inc. News Releases 8026 Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA http://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeutics-submits-ind-application-ons-5010-fda CRANBURY, N.J. , March 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today the submission of its Investigational New Drug (IND) application with the U.S. Food and Drug Administration ( FDA ) for ONS-5010. Fri, 01 Mar 2019 08:00:00 -0500 Outlook Therapeutics, Inc. News Releases 8016 Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019 http://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeutics-provides-business-update-and-reports-first CRANBURY, N.J. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported financial results and business highlights for its first fiscal quarter ended December 31, 2018 . Recent Highlights: Reached 75% enrollment completion in ONS-5010-001, a Phase 3 Thu, 14 Feb 2019 08:00:00 -0500 Outlook Therapeutics, Inc. News Releases 7966 Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement http://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeutics-closes-final-tranche-20-million-private CRANBURY, N.J. , Feb. 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it closed on the final tranche (of four) of its $20.0 million private placement of common stock to BioLexis Pte. Limited (BioLexis), the Company’s strategic business Fri, 01 Feb 2019 09:15:00 -0500 Outlook Therapeutics, Inc. News Releases 7936 Outlook Therapeutics Announces Exercise Price Reduction and Term Extension of Series A Warrants http://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeutics-announces-exercise-price-reduction-and-term CRANBURY, N.J. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK, OTLKW) (the “Company”) today announced that its publicly traded Series A warrants (Nasdaq: OTLKW) have been amended to lower the exercise price to $1.50 per share and further extend the maturity until 5:00 Tue, 22 Jan 2019 09:00:00 -0500 Outlook Therapeutics, Inc. News Releases 7916